Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 13/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 0.79 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.79 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.79 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.79 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.79 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.79 |
| ▸ | GC | P02774 | 1/20 | 0.79 |
| ▸ | PGR | P06401 | 1/20 | 0.79 |
| ▸ | RXRA | P19793 | 1/20 | 0.79 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.79 |
| ▸ | CNR1 | P21554 | 1/20 | 0.79 |
| ▸ | HTR2C | P28335 | 1/20 | 0.79 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.79 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.79 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.79 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.79 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.79 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.79 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maxacalcitol SCHEMBL5617045 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Maxacalcitol SCHEMBL20460962 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Maxacalcitol SCHEMBL5153671 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Maxacalcitol SCHEMBL25095406 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Maxacalcitol SCHEMBL8079072 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Maxacalcitol SCHEMBL24066887 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Maxacalcitol SCHEMBL20460998 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Maxacalcitol SCHEMBL7084224 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Maxacalcitol SCHEMBL15263550 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Maxacalcitol SCHEMBL14117375 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1179346-B1 | REMEDIES FOR GLOMERULOSCLEROSIS | DOI TOSHIO (JP) | 2006-08-09 | — | — | EP | claimed |
| US-6864247-B2 | Therapeutic agents for glomerulosclerosis | DOI TOSHIO (JP) | 2005-03-08 | — | — | US | claimed |
| US-20040248859-A1 | Medicinal compositions for treating secondary parathyroid hyperfunction and remedies for cardiovascular complications in association with treatment for secondary parathyroid hyperfunction | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-12-09 | — | — | US | claimed |
| EP-1402893-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF SECONDARY HYPERPARATHYROIDISM AND THERAPEUTIC AGENTS FOR CARDIOVASCULAR COMPLICATIONS RESULTING FROM THE TREATMENT FOR SECONDARY HYPERPARATHYROIDISM. | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-03-31 | — | — | EP | claimed |
| US-20030083320-A1 | Therapeutic agents for glomerulosclerosis | DOI TOSHIO (JP) | 2003-05-01 | — | — | US | claimed |
| US-6506741-B1 | Remedies for glomerulosclerosis | DOI TOSHIO (JP) | 2003-01-14 | — | — | US | claimed |
| EP-1179346-A1 | REMEDIES FOR GLOMERULOSCLEROSIS | Doi, Toshio (JP) | 2002-02-13 | — | — | EP | claimed |
| EP-0385446-B1 | Osteogenesis promotion with use of vitamin D derivatives | CHUGAI PHARMACEUTICAL CO LTD (JP) | 1995-12-06 | — | — | EP | claimed |
| JP-2289519-A | — | — | None | — | — | JP | disclosed |
| JP-6199776-A | — | — | None | — | — | JP | disclosed |
| EP-3056491-B1 | SYNTHETIC INTERMEDIATE OF MAXACALCITOL, PREPARATION METHOD THEREFOR AND USE THEREOF | ZHEJIANG HISUN PHARM CO LTD (CN) | 2018-08-08 | — | — | EP | disclosed |
| US-20160237030-A1 | SYNTHETIC INTERMEDIATE OF MAXACALCITOL, PREPARATION METHOD THEREFOR AND USE THEREOF | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2016-08-18 | — | — | US | disclosed |
| EP-3056491-A1 | SYNTHETIC INTERMEDIATE OF MAXACALCITOL, PREPARATION METHOD THEREFOR AND USE THEREOF | Zhejiang Hisun Pharmaceutical Co. Ltd. (CN) | 2016-08-17 | — | — | EP | disclosed |
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES AG (AT) | 2014-11-27 | — | — | US | disclosed |
| US-5436401-A | 22-oxacholecalciferol derivative and process for preparing the same | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1995-07-25 | — | — | US | disclosed |
| EP-0619304-A1 | 22-OXACHOLECALCIFEROL DERIVATIVE AND PRODUCTION THEREOF | Chugai Seiyaku Kabushiki Kaisha (JP) | 1994-10-12 | — | — | EP | disclosed |
| JP-H06199776-A | VITAMIN D DERIVATIVE AND PRODUCTION OF VITAMIN D USING THE SAME | CHUGAI PHARMACEUT CO LTD | 1994-07-19 | — | — | JP | disclosed |
| JP-H02289519-A | BONE FORMATION PROMOTER | CHUGAI PHARMACEUT CO LTD | 1990-11-29 | — | — | JP | disclosed |
| US-4891364-A | MINIMIZED EFFECT ON CALCIUM METABOLISM | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1990-01-02 | — | — | US | disclosed |
| EP-0184112-A2 | Novel vitamin D derivatives and process for producing the same | Chugai Seiyaku Kabushiki Kaisha (JP) | 1986-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | TRPV1, ACHE, OPRL1 | VDR 869/4885MAPT 898/4885ADORA3 180/4885 |
| US-20160237030-A1 | SYNTHETIC INTERMEDIATE OF MAXACALCITOL, PREPARATION METHOD THEREFOR AND USE THEREOF | CYP24A1, CYP2R1, CYP27B1 | VDR 9/4885MAPT 4136/4885ADORA3 1497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.